Mangalam Drugs — 360° view

Mangalam Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹79 crore and a net loss of ₹7.21 crore for the September 2026 quarter.

Mangalam Drugs (NSE: MANGALAM) closed at ₹27.55 on 20 Nov 2026. Its market capitalisation is ₹44 crore.

Share price
₹27.55 (20 Nov 2026)
Market cap
₹44 Cr (20 Nov 2026)
Revenue
₹79 Cr (September 2026 quarter)
Net profit
₹-7 Cr (September 2026 quarter)
ROCE
-13.8% (FY26)
ROE
-34.8% (FY26)
Book value
₹55.8 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹38.25 / ₹25.70 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: MANGALAM

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.